Esther Rajavelu Sells 87,917 Shares of Spero Therapeutics (NASDAQ:SPRO) Stock

Spero Therapeutics, Inc. (NASDAQ:SPRO) insider Esther Rajavelu sold 87,917 shares of the firm’s stock in a transaction on Friday, February 6th. The shares were sold at an average price of $2.36, for a total transaction of $207,484.12. Following the sale, the insider owned 1,012,091 shares in the company, valued at $2,388,534.76. The trade was a 7.99% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink.

Esther Rajavelu also recently made the following trade(s):

• On Monday, February 2nd, Esther Rajavelu sold 18,442 shares of Spero Therapeutics stock. The stock was sold at an average price of $2.20, for a total transaction of $40,572.40.

Spero Therapeutics Stock Down 2.5%

SPRO stock traded down $0.06 during trading on Monday, reaching $2.36. The company’s stock had a trading volume of 349,025 shares, compared to its average volume of 328,467. The company’s fifty day moving average is $2.35 and its 200-day moving average is $2.24. The company has a market capitalization of $132.96 million, a P/E ratio of -2.99 and a beta of 1.45. Spero Therapeutics, Inc. has a 1 year low of $0.51 and a 1 year high of $3.22.

Spero Therapeutics (NASDAQ:SPRO) last released its quarterly earnings data on Thursday, November 13th. The company reported ($0.13) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.25) by $0.12. The firm had revenue of $5.44 million during the quarter, compared to analyst estimates of $12.00 million. Spero Therapeutics had a negative return on equity of 125.91% and a negative net margin of 108.11%. Analysts anticipate that Spero Therapeutics, Inc. will post -1.2 earnings per share for the current year.

Institutional Trading of Spero Therapeutics

Several hedge funds have recently made changes to their positions in SPRO. Invesco Ltd. purchased a new position in Spero Therapeutics in the second quarter worth about $43,000. Dimensional Fund Advisors LP bought a new stake in shares of Spero Therapeutics in the 3rd quarter valued at approximately $55,000. Assenagon Asset Management S.A. purchased a new position in shares of Spero Therapeutics in the 3rd quarter worth approximately $70,000. Quadrature Capital Ltd purchased a new position in shares of Spero Therapeutics in the 2nd quarter worth approximately $90,000. Finally, Two Sigma Investments LP purchased a new stake in Spero Therapeutics during the 3rd quarter valued at $93,000. 25.60% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

Several research firms have recently commented on SPRO. Wall Street Zen raised shares of Spero Therapeutics from a “hold” rating to a “buy” rating in a report on Sunday, January 11th. Zacks Research cut shares of Spero Therapeutics from a “strong-buy” rating to a “hold” rating in a research note on Monday, October 13th. Finally, Weiss Ratings restated a “sell (d-)” rating on shares of Spero Therapeutics in a research report on Thursday, January 22nd. One equities research analyst has rated the stock with a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat, Spero Therapeutics currently has an average rating of “Reduce”.

About Spero Therapeutics

Spero Therapeutics is a clinical‐stage biopharmaceutical company focused on the discovery and development of novel therapies to address multidrug‐resistant bacterial infections. Headquartered in Boston, Massachusetts, the company aims to advance a pipeline of oral and intravenous antibiotic candidates designed to treat serious infectious diseases that pose significant public health challenges.

The company’s lead candidate, tebipenem HBr, is an oral carbapenem antibiotic being developed for the treatment of complicated urinary tract infections caused by resistant Gram‐negative pathogens.